Boron and menstrual pain
Duration and intensity of menstrual pain in a sodium tetraborate study.
Key points
- In female students with moderate or severe primary menstrual pain, pain duration in the second of two cycles was shorter with sodium tetraborate than with placebo. For participants with such symptoms, this is a preliminary indication that time in pain may be shorter. [1] See the evidence 1
- The study found no convincing advantage of sodium tetraborate over placebo in change in menstrual pain intensity. This comparison does not support relying on a confirmed reduction in pain intensity. [1] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
Pain duration and intensity were assessed separately.
Key points
Why these conclusions
Two-cycle study
Female students with moderate or severe primary menstrual pain received 10 mg elemental boron in 88.5 mg sodium tetraborate or placebo from two days before menstruation through the third day of bleeding for two cycles. In the second cycle pain duration was shorter with the studied form; no convincing advantage in change in intensity was found. [1]
Excess boron can cause nausea, vomiting, diarrhea and severe poisoning. Upper levels for long-term total intake in adults: EFSA 10 mg/day; United States for people aged 19 and older 20 mg/day; these are neither supplement doses nor thresholds guaranteeing harm. [2] [3]
In the second cycle pain scores were 4.35 versus 5.87 points; the between-group difference in changes did not reach statistical significance.
| Parameter | Data |
|---|---|
| Result | In the second cycle pain scores were 4.35 versus 5.87 points; the between-group difference in changes did not reach statistical significance. Second-cycle scores 4.35 versus 5.87 out of 10; baseline 5.90 versus 6.44. For comparison of changes p=0.074. |
| Participants | Female students in Iran with moderate or severe primary dysmenorrhea; 59/59 enrolled, 58/55 analyzed |
| Form | Sodium tetraborate |
| Dose | 10 mg elemental boron daily in 88.5 mg sodium tetraborate |
| Dose basis | 10 mg elemental boron daily in 88.5 mg sodium tetraborate |
| Comparator | Capsule containing 300 mg lactose |
| Duration | Two cycles: daily from two days before menstruation through the third day of bleeding |
| Confidence | 1/4: Precision: very serious limitation: one small trial without a confidence interval for the group-by-time interaction or adjusted change; the longitudinal comparison does not distinguish an effect from no effect, while the final difference includes baseline imbalance.; Consistency: one suitable independent trial; consistency cannot be assessed, which alone is not grounds for downgrading.; Applicability: directly concerns the specified group, intervention and outcome; no transfer beyond them is intended.; Possible publication bias: insufficient data to establish publication bias in one small evidence base; no separate downgrade.; Study methods: serious limitation: blocking by symptom severity and triple blinding strengthen design, but allocation concealment was not described, 1 and 4 participants dropped out without analysis of all randomized participants; ratings were subjective and analyses multiple. |
| Evidence base | 1 trial |
| Sources | [1] |
In the second cycle pain lasted an average of 2.74 hours versus 4.08 hours with placebo.
| Parameter | Data |
|---|---|
| Result | In the second cycle pain lasted an average of 2.74 hours versus 4.08 hours with placebo. In the second cycle 2.74 versus 4.08 hours; baseline 4.15 versus 4.46 hours; comparison of changes p=0.020. |
| Participants | Female students in Iran with moderate or severe primary dysmenorrhea; 59/59 enrolled, 58/55 analyzed |
| Form | Sodium tetraborate |
| Dose | 10 mg elemental boron daily in 88.5 mg sodium tetraborate |
| Dose basis | 10 mg elemental boron daily in 88.5 mg sodium tetraborate |
| Comparator | Capsule containing 300 mg lactose |
| Duration | Two cycles: daily from two days before menstruation through the third day of bleeding |
| Confidence | 2/4: Precision: serious limitation: 113 people analyzed; no confidence interval for the group-by-time interaction or adjusted effect; unadjusted results do not determine the exact magnitude.; Consistency: one suitable independent trial; consistency cannot be assessed, which alone is not grounds for downgrading.; Applicability: directly concerns the specified group, intervention and outcome; no transfer beyond them is intended.; Possible publication bias: insufficient data to establish publication bias in one small evidence base; no separate downgrade.; Study methods: serious limitation: blocking by symptom severity and triple blinding strengthen design, but allocation concealment was not described, 1 and 4 participants dropped out without analysis of all randomized participants; ratings were subjective and analyses multiple. |
| Evidence base | 1 trial |
| Sources | [1] |
Excess boron can cause nausea, vomiting, diarrhea and severe poisoning. Upper levels for long-term total intake in adults: EFSA 10 mg/day; United States for people aged 19 and older 20 mg/day; these are neither supplement doses nor thresholds guaranteeing harm.
Excess boron can cause nausea, vomiting, diarrhea and severe poisoning. Upper levels for long-term total intake in adults: EFSA 10 mg/day; United States for people aged 19 and older 20 mg/day; these are neither supplement doses nor thresholds guaranteeing harm. [2] [3]
More details
How to interpret the results
The preliminary signal concerns pain duration in the studied group and specific compound; intensity was assessed separately. [1]
Sources
- Effects of boron supplementation on the severity and duration of pain in primary dysmenorrhea. https://pubmed.ncbi.nlm.nih.gov/25906949/
- Boron - Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/Boron-HealthProfessional/
- Summary of Tolerable Upper Intake Levels for minerals. https://www.efsa.europa.eu/sites/default/files/2023-11/ul_summary_tables-version-8.pdf
Methodology: Subpages evidence-led supplement pipeline v1